]>
IRCT20190914044769N1 IRCT 2020-03-07 Mashhad University of Medical Sciences Effect of Pentoxifylline in treatment of schizophrenia The efficacy of pentoxifylline adjunctive therapy on cognitive deficits and symptoms of patients with schizophrenia: A randomized placebo-controlled clinical trial 2020-01-21 anticipated 52 Complete https://irct.ir/trial/42144 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: simple randomization, Blinding description: The drugs and placebo are packaged and numbered by the pharmacist and provided to the researcher and then the therapeutic units. Study participants were unaware that the drug they were taking was a drug or a placebo, knowing that the drug was added to other drugs to improve their condition. The lead researcher, who drafts the article, entered the patients and prescribed the medication in their prescription don't know which patients are given the drug or placebo. Nurses who take care of patients and give patients drugs have been kept blind in the study because they give the medicine from the same numbered envelopes to the patients, and the doctors who check the medication's side effects; They have been kept blind from the study. Data collectors and those assessing outcomes also lack information on drug and placebo groups. 3 schizophrenia. To the intervention group is given 400mg extended release pentoxifylline pills from Hakim Pharmaceutical Company every 8 hours for 2 months. Pentoxifylline is a class of aminophyllins.. Yes - There is a plan to make this available What will be shared: The full statistical report will be published in detail on the data of the questionnaires in the paper. When: from 2020 To whom: The data report will be published in the article. Conditions: The data report will be published in the article. Where to obtain: The data report will be published in the article. How to obtain: The data report will be published in the article. Comments:
public Fsrhad Faridhoseini
Bou-Ali square., Hor Ameli blvd., Ibn-Sina hospital
Mashhad Iran (Islamic Republic of) 919583134 +98 51 337002201 faridhoseinif@mums.ac.ir Mashhad University of Medical Sciences scientific Farhad Faridhoseini
Bou-Ali square., Hor Ameli blvd., Ibn-Sina hospital
Mashhad Iran (Islamic Republic of) 919583134 +98 51 337002201 FaridhoseiniF@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Diagnosis of schizophrenia based on DSM-5 criteria Patients aged 18-55 years Completion of the consent form by the patient or his / her family Education level at least eighth grade Absence of other concurrent psychiatric disorders Absence of liver and kidney disorders Absence of medical illness leads to psychiatric symptoms No substance use except for smoking Absence of serious cognitive impairment Absence of risk factor for bleeding Patients who are prescribed antipsychotics for risperidone, olanzapine or aripiperazole. Onset of illness under 45 years 18 years 55 years Both Hypersensitivity reaction or any unbearable side effect caused by the drug Unwillingness to continue taking the drug and continue the project F20 Schizophrenia Treatment - Drugs To the intervention group is given 400mg extended release pentoxifylline pills from Hakim Pharmaceutical Company every 8 hours for 2 months. Pentoxifylline is a class of aminophyllins. Cognitive scores according to Stroop, Ray, Digit span, and Wisconcin card sorting test. Timepoint: Evaluation of cognitive impairments and positive and negative symptoms of schizophrenia at baseline (before intervention) and 4 and 8 weeks after starting pentoxifylline. Method of measurement: Positive and Negative Syndrome Scale, cognitive tests include Stroop, Ray, Digit span, and Wisconcin card sorting test. Score of Positive and Negative Syndrome Scale. Timepoint: Baseline (before intervention) and 4 and 8 weeks after starting pentoxifylline. Method of measurement: Positive and Negative Syndrome Scale. Mashhad University of Medical Sciences Approved 2019-06-09 Iran national committee for ethics in biomedical research Floor 13, Block A, Ministry of Health & Medical Education Headquarters, Between Zarafashan & South Falamak, Qods Town, Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)